Literature DB >> 9626921

Effect of omeprazole on the pharmacokinetics of itraconazole.

S Jaruratanasirikul1, S Sriwiriyajan.   

Abstract

OBJECTIVE: To investigate the effect of omeprazole on the pharmacokinetics of itraconazole.
METHODS: Eleven healthy volunteers received a single dose of oral itraconazole (200 mg) on days 1 and 15 and oral omeprazole (40 mg) once daily from day 2 to day 15. Itraconazole pharmacokinetics were studied on days 1 and 15.
RESULTS: Concentrations of itraconazole were higher when it was taken alone than when it was taken with omeprazole. With concomitant omeprazole treatment, the mean AUC0-24 and Cmax of itraconazole were significantly reduced by 64% and 66%, respectively.
CONCLUSION: Omeprazole affects itraconazole kinetics, leading to a reduction in bioavailability and Cmax. These two drugs should not be used together.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626921     DOI: 10.1007/s002280050438

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

2.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 3.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Inhibition of antifungal therapy by gastric acid suppressants.

Authors:  Harry W Daniell
Journal:  Intensive Care Med       Date:  2015-02-21       Impact factor: 17.440

Review 5.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

6.  Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Stuart Mudge; David Hayes; Richard N Upton
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

Review 7.  Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.

Authors:  Takahisa Furuta; Mitsushige Sugimoto; Naohito Shirai
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

8.  Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers.

Authors:  Ahmad Y Abuhelwa; Stuart Mudge; Richard N Upton; David J R Foster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.441

Review 9.  Endemic Mycoses in Solid Organ Transplant Recipients.

Authors:  Jeremy S Nel; Luther A Bartelt; David van Duin; Anne M Lachiewicz
Journal:  Infect Dis Clin North Am       Date:  2018-09       Impact factor: 5.982

10.  Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.

Authors:  Marc R Yago; Adam R Frymoyer; Gillian S Smelick; Lynda A Frassetto; Nageshwar R Budha; Mark J Dresser; Joseph A Ware; Leslie Z Benet
Journal:  Mol Pharm       Date:  2013-09-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.